Adenine nucleotides decrease the apparent Km of endogenous natriuretic peptide receptors for GTP.
Natriuretic peptide receptors A (NPR-A) and B (NPR-B) mediate most effects of natriuretic peptides by synthesizing cGMP. ATP increases the activity of these receptors by an unknown mechanism. We recently reported that a nonhydrolyzable form of ATP, adenylyl imidodiphosphate (AMPPNP), stabilizes but is not required for the activation of NPR-A and NPR-B in membranes from highly overexpressing cells. Here, we repeated these studies on receptors expressed in endogenous settings. Kinetic analysis indicated that both AMPPNP and ATP dramatically decrease the apparent K(m) of both receptors for GTP but had little effect on the V(max). The EC(50) for AMPPNP decreased as substrate concentration increased whereas the magnitude of the effect was greater at lower GTP concentrations. ATP increased the activity of a mutant receptor containing glutamates substituted for all known phosphorylation sites similarly to the wild-type receptor, consistent with a phosphorylation independent mechanism. Finally, the putative ATP binding sites were investigated. Mutation of the ATP modulatory domain region had no effect, but mutation of K535A dramatically diminished ANP-dependent cyclase activity in a manner that was unresponsive to ATP. Mutation of the highly conserved 630-KSS to AAA (all alanines) resulted in an expressed receptor that had no detectable guanylyl cyclase activity. We conclude that ATP is not required for the initial activation of NPRs but does increase activity over time by reducing the apparent K(m) for GTP.
Antos
Laura K
LK
Dept. of Biochemistry, Molecular Biology and Biophysics, Univ. of Minnesota, 6-155 Jackson, 321 Church St. SE, Minneapolis, MN 55455, USA.
Potter
Lincoln R
LR
D000227:Adenine Nucleotides / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000032:analysis / Q000494:pharmacology; D000266:Adenylyl Imidodiphosphate / Q000494:pharmacology; D000494:Allosteric Regulation; D000495:Allosteric Site; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D002384:Catalysis / Q000187:drug effects; D002417:Cattle; D002460:Cell Line; D002462:Cell Membrane / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D006160:Guanosine Triphosphate / Q000378:metabolism* / Q000494:pharmacology; D006162:Guanylate Cyclase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D051379:Mice; D009154:Mutation; D041681:NIH 3T3 Cells; D020098:Natriuretic Peptide, C-Type / Q000494:pharmacology; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D000099242:Atrial Natriuretic Factor Receptor B
D000227:Adenine Nucleotides; D000255:Adenosine Triphosphate; D000266:Adenylyl Imidodiphosphate; D009320:Atrial Natriuretic Factor; D006160:Guanosine Triphosphate; D006162:Guanylate Cyclase; D020098:Natriuretic Peptide, C-Type; D017461:Receptors, Atrial Natriuretic Factor; D000099242:Atrial Natriuretic Factor Receptor B; C036852:magnesium GTP; C091715:atrial natriuretic factor receptor A